Combination Therapy Sequencing in Parkinson's Disease

Combination Therapy Sequencing in Parkinson's Disease

Experiment Overview

Rank: 108 | Score: 74/100 | Category: Translational | Disease: Parkinson's Disease

Hypothesis

Combination therapy with optimized sequencing will slow motor and non-motor progression in PD more effectively than any single mechanism or standard symptomatic treatment.

Knowledge Gap Addressed

Addresses the "Therapy Sequencing for Disease-Modifying Combinations in Neurodegeneration" gap — specifically, how to sequence alpha-synuclein targeting, neuroprotective, and dopaminergic therapies in PD.

Scientific Rationale

Combination Therapy Sequencing in Parkinson's Disease

Experiment Overview

Rank: 108 | Score: 74/100 | Category: Translational | Disease: Parkinson's Disease

Hypothesis

Combination therapy with optimized sequencing will slow motor and non-motor progression in PD more effectively than any single mechanism or standard symptomatic treatment.

Knowledge Gap Addressed

Addresses the "Therapy Sequencing for Disease-Modifying Combinations in Neurodegeneration" gap — specifically, how to sequence alpha-synuclein targeting, neuroprotective, and dopaminergic therapies in PD.

Scientific Rationale

Parkinson's disease involves multiple pathological mechanisms:

• Alpha-synuclein aggregation (intracellular and extracellular)
• Dopaminergic neuron loss in substantia nigra
• Mitochondrial dysfunction
• Neuroinflammation
• Lewy body pathology spread

Why This Matters

• PD affects 6 million people globally
• Current therapies only treat symptoms, not progression
• Combination approaches borrowed from oncology may work
• Early intervention likely more effective

Validation Protocol

Study Design

Type: Multi-arm adaptive platform trial

Population:

• Early PD (disease duration <3 years)
• Age 40-75
• Motor phenotype (tremor-dominant or PIGD)
• No dementia (MoCA >26)

Disease-Modifying Mechanisms Tested

| Mechanism | Agent | Dose |
|-----------|-------|-----|
| Alpha-synuclein reduction | GLP-1 receptor agonist (exenatide) | 2mg weekly |
| Neuroprotection | Inosine (urate elevation) | Titrate to 6-8 mg/dL |
| Anti-inflammatory | Sargramostim (GM-CSF) | 6 μg/kg daily |
| Antioxidant | CoQ10 | 300mg BID |

Sequencing Arms

Arm A (Early Combination):

• Month 0: All three non-dopaminergic mechanisms
• Month 12: Add dopaminergic if needed

• Month 0-6: GLP-1 agonist first
• Month 6-12: Add urate
• Month 12-18: Add anti-inflammatory
• Month 18+: Add dopaminergic

• Baseline biomarkers determine initial choice
• 6-month biomarker reassessment drives additions

• Standard of care (symptomatic treatment only)

Biomarker Endpoints

| Biomarker | Purpose |
|----------|---------|
| Alpha-syn RT-QuIC (CSF) | Alpha-synuclein seeding |
| NfL (plasma) | Neurodegeneration rate |
| Urate | Antioxidant response |
| cytokines (CSF) | Inflammation markers |
| DaTscan | Dopaminergic integrity |

Sample Size

n=400 (100 per arm)

• Power: 80% to detect 30% slower progression
• Alpha: 0.05

Duration

36 months total

• 24-month primary endpoint
• Extended follow-up

Model Systems

Preclinical Validation

• MPTP/6-OHDA mouse models with drug combinations
• Alpha-synuclein preformed fibril mouse models
• iPSC-derived dopaminergic neurons from PD patients

Combination Screening

• High-throughput drug combination screening
• Synergy scoring for mechanism pairs
• Dose-response matrices

Expected Outcomes

Primary Endpoint

• MDS-UPDRS total change at 24 months
• Comparing combination arms to control

Secondary Endpoints

Hypothesized Results

• Staged combination reduces MDS-UPDRS by 8-15 points vs control
• Delays motor fluctuations by 12-18 months
• Preserves DaT signal longer

Feasibility Assessment

Technical Feasibility: 7/10

• All agents available and repurposed
• Biomarker assays established
• Trial infrastructure exists

Cost Estimate

| Component | Cost |
|-----------|------|
| Drug acquisition | $4,200/patient |
| Biomarker testing | $2,400/patient |
| Clinical visits | $3,000/patient |
| Imaging | $1,800/patient |
| Total | $11,400/patient |
| Project total | $4.6M |

Timeline

• Preparation: 9 months
• Enrollment: 24 months
• Follow-up: 12 months
• Analysis: 4 months
• Total: 49 months

Risk Mitigation

Risks and Mitigations

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| Drug interactions | Medium | High | Safety monitoring |
| Tolerability | Medium | Medium | Dosetitration |
| Non-PD medication exclusion | Medium | Medium | Strict screening |

Stopping Rules

• >10% severe adverse events: Review arm
• Clear efficacy: Early termination for benefit
• Clear harm: Terminate arm

Cross-Disease Value

Sequencing logic developed here applies to:

• AD combination therapy sequencing
• ALS multi-target approaches
• FTD genotype-specific combinations

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Combination Therapy Sequencing in Parkinson's Disease discovered through SciDEX knowledge graph analysis: